GlobeNewswire: Catalyst Biosciences, Inc. Contains the last 10 of 184 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:53:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/09/15/2297462/0/en/Catalyst-Biosciences-Participating-in-a-Fireside-Chat-with-LifeSci-Capital.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital2021-09-15T12:00:00Z<![CDATA[Management to discuss CBIO’s complement portfolio including the potential of CB 2782-PEG in dry AMD Management to discuss CBIO’s complement portfolio including the potential of CB 2782-PEG in dry AMD]]>https://www.globenewswire.com/news-release/2021/09/09/2294275/0/en/Catalyst-Biosciences-Announces-Oral-and-Poster-Presentations-at-the-International-Conference-on-Complement-Therapeutics.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Announces Oral and Poster Presentations at the International Conference on Complement Therapeutics2021-09-09T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021.]]>https://www.globenewswire.com/news-release/2021/09/08/2293368/0/en/Catalyst-Biosciences-Announces-Appointment-of-Jeanne-Jew-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Announces Appointment of Jeanne Jew to its Board of Directors2021-09-08T12:00:00Z<![CDATA[Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise]]>https://www.globenewswire.com/news-release/2021/08/05/2275523/0/en/Catalyst-Biosciences-Reports-Second-Quarter-2021-Operating-Financial-Results-and-Provides-a-Corporate-Update.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update2021-08-05T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2021/07/22/2267242/0/en/Catalyst-Biosciences-Announces-First-Patient-Screened-for-CFI-deficiency-in-its-CB-4332-Screening-and-Natural-History-of-Disease-Studies.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies2021-07-22T12:00:00Z<![CDATA[Launching the ConFIrm study to identify patients with Complement Factor I deficiencies Launching the ConFIrm study to identify patients with Complement Factor I deficiencies]]>https://www.globenewswire.com/news-release/2021/07/19/2265154/0/en/Catalyst-Biosciences-Presents-Four-Posters-at-the-International-Society-for-Thrombosis-and-Haemostasis-ISTH-2021-Virtual-Congress.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress2021-07-19T20:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress, being held July 17-21, 2021.]]>https://www.globenewswire.com/news-release/2021/07/14/2262715/0/en/Catalyst-Biosciences-Announces-Key-Leadership-Changes-in-its-Ongoing-Transition-to-an-Integrated-Protease-Medicines-Company.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Announces Key Leadership Changes in its Ongoing Transition to an Integrated Protease Medicines Company2021-07-14T12:00:00Z<![CDATA[Grant Blouse, Ph.D., M.Sc. appointed chief scientific officer]]>https://www.globenewswire.com/news-release/2021/07/06/2258147/0/en/Catalyst-Biosciences-Announces-Presentations-at-the-International-Society-on-Thrombosis-and-Haemostasis.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis2021-07-06T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and dalcinanonog alfa (DalcA) at the upcoming International Society on Thrombosis and Haemostatis (ISTH) Virtual Congress being held from July 17-21, 2021.]]>https://www.globenewswire.com/news-release/2021/07/01/2256455/0/en/Catalyst-Biosciences-to-Host-Research-and-Development-Day-on-CB-4332-and-Complement-Programs.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs2021-07-01T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development day on its protease medicines platform focusing on the regulation of complement including CB 4332 on Monday, July 19, 2021 at 12:00 pm Eastern Time.]]>https://www.globenewswire.com/news-release/2021/06/28/2253826/0/en/Catalyst-Biosciences-Receives-FDA-Fast-Track-Designation-for-Subcutaneous-MarzAA-for-the-Treatment-of-Episodic-Bleeding-in-Factor-VII-Deficiency.html?f=22&fvtc=4&fvtv=26101Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency2021-06-28T12:00:00Z<![CDATA[Second Fast Track Designation for MarzAA Second Fast Track Designation for MarzAA]]>